- Home
- ACTG vs CLLS Comparison
ACTG vs CLLS Comparison
Compare ACTG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTG
- CLLS
- Stock Information
- Founded
- ACTG 1993
- CLLS 1999
- Country
- ACTG United States
- CLLS France
- Employees
- ACTG N/A
- CLLS N/A
- Industry
- ACTG Multi-Sector Companies
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ACTG Miscellaneous
- CLLS Health Care
- Exchange
- ACTG Nasdaq
- CLLS Nasdaq
- Market Cap
- ACTG 314.4M
- CLLS 299.0M
- IPO Year
- ACTG 1996
- CLLS 2007
- Fundamental
- Price
- ACTG $3.40
- CLLS $4.30
- Analyst Decision
- ACTG
- CLLS Buy
- Analyst Count
- ACTG 0
- CLLS 1
- Target Price
- ACTG N/A
- CLLS $4.00
- AVG Volume (30 Days)
- ACTG 169.2K
- CLLS 161.1K
- Earning Date
- ACTG 11-11-2025
- CLLS 11-03-2025
- Dividend Yield
- ACTG N/A
- CLLS N/A
- EPS Growth
- ACTG N/A
- CLLS N/A
- EPS
- ACTG N/A
- CLLS N/A
- Revenue
- ACTG $247,813,000.00
- CLLS $63,438,000.00
- Revenue This Year
- ACTG $109.86
- CLLS N/A
- Revenue Next Year
- ACTG N/A
- CLLS $66.76
- P/E Ratio
- ACTG N/A
- CLLS N/A
- Revenue Growth
- ACTG 62.44
- CLLS 223.09
- 52 Week Low
- ACTG $2.70
- CLLS $1.10
- 52 Week High
- ACTG $5.36
- CLLS $4.53
- Technical
- Relative Strength Index (RSI)
- ACTG 53.63
- CLLS 74.29
- Support Level
- ACTG $3.18
- CLLS $3.36
- Resistance Level
- ACTG $3.39
- CLLS $3.60
- Average True Range (ATR)
- ACTG 0.09
- CLLS 0.24
- MACD
- ACTG 0.01
- CLLS 0.08
- Stochastic Oscillator
- ACTG 75.47
- CLLS 96.51
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.